Celgene, Novartis File Ritalin Patent Suit

Law360, New York (November 2, 2007, 12:00 AM EDT) -- Pharmaceutical companies Celgene Corp. and Novartis AG continue to fight back against attempts to market a generic time-release version of Ritalin, a drug used to treat attention deficit/hyperactive disorder.

The companies filed a suit Wednesday against Barr Laboratories, Inc. in the U.S. District Court for the District of New Jersey. The legal battle follows a similar suit the companies filed against generics maker Abrika Pharmaceuticals Inc. in February.

The suit was filed after Barr filed an Abbreviated New Drug Application to market generic capsules of Ritalin...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.